Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The advanced glycation end product (AGE) formation pathway is a series of non-enzymatic chemical reactions in which reducing sugars react with proteins, lipids, or nucleic acids, leading to the formation of AGEs. This process involves the Maillard reaction, polyol pathway, lipid peroxidation, Wolff pathway, and Namiki pathway, and is implicated in the pathogenesis of various chronic diseases and aging-related tissue damage. Key intermediates include Schiff bases, Amadori products, methylglyoxal, and glyoxal. AGEs accumulate and lead to protein cross-linking, loss of protein function, increased tissue stiffness, and activation of inflammatory signaling via specific receptors such as RAGE, AGE-R1, AGE-R2 and AGE-R3.
Inhibition of AGE formation, scavenging of AGEs or AGE precursors, blocking AGE receptor interaction
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Advanced Glycation End Product Formation Pathway (AGE Pathway).